79
Participants
Start Date
May 31, 2012
Primary Completion Date
September 1, 2015
Study Completion Date
September 24, 2015
Belimumab plus Early Vaccination
Belimumab 10 mg/kg IV plus standard therapy for SLE is administered on Days 28, 42, 56, and every 28 days thereafter through Week 32 (9 doses). Pneumococcal vaccination is administered 4 weeks prior to the first dose of belimumab.
Belimumab plus Late Vaccination
Belimumab 10 mg/kg IV plus standard therapy for SLE is administered on Days 0, 14, 28, and then every 28 days thereafter through Week 28 (9 doses). Pneumococcal vaccination is administered 24 weeks after the first dose of belimumab.
GSK Investigational Site, New York
GSK Investigational Site, Duncansville
GSK Investigational Site, Baltimore
GSK Investigational Site, Cumberland
GSK Investigational Site, Hagerstown
GSK Investigational Site, Birmingham
GSK Investigational Site, Toledo
GSK Investigational Site, Shreveport
GSK Investigational Site, Houston
GSK Investigational Site, Austin
GSK Investigational Site, Austin
GSK Investigational Site, Paradise Valley
GSK Investigational Site, Seattle
GSK Investigational Site, Spokane
GSK Investigational Site, Burlington
Collaborators (1)
GlaxoSmithKline
INDUSTRY
Human Genome Sciences Inc., a GSK Company
INDUSTRY